Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Therma Bright Inc (OP: TBRIF )

0.0230 -0.0005 (-2.13%)
Streaming Delayed Price Updated: 1:15 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Therma Bright Inc

< Previous 1 2 3 Next >
Therma Bright Receives Payment for Initial Venowave Sales
Toronto, Ontario--(Newsfile Corp. - September 20, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Supply Chain
Therma Bright Provides Update on FDA EUA Review Process
Toronto, Ontario--(Newsfile Corp. - September 12, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Product Safety Supply Chain
Therma Bright Provides Progress Update on FDA EUA & Health Canada Interim Order Applications for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario--(Newsfile Corp. - August 4, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)
Toronto, Ontario--(Newsfile Corp. - June 23, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Provides Update on FDA EUA Application Process For AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario--(Newsfile Corp. - June 2, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright to Submit Application to Health Canada for Approval of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario--(Newsfile Corp. - May 10, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical... 
Via Newsfile
Topics Supply Chain
Exposures COVID-19 Product Safety Supply Chain
Therma Bright Ships Initial Venowave Order to US Distributor
Toronto, Ontario--(Newsfile Corp. - April 28, 2022) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical... 
Via Newsfile
Exposures COVID-19
Therma Bright Submits AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Application for U.S. Food & Drug Administration's Emergency Use Authorization (EUA)
Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Receives Patent for a Device for Applying a Topical Treatment from U.S. Patent & Trademark Office (USPTO)
Toronto, Ontario--(Newsfile Corp. - February 23, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Therma Bright's AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration's Emergency Use Authorization Requirements
Toronto, Ontario--(Newsfile Corp. - February 15, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Completes U.S. Clinical Performance Study Subject Recruitment
Toronto, Ontario--(Newsfile Corp. - January 31, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Provides Update on U.S. Clinical Performance Study
Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test's Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 Variant
Toronto, Ontario--(Newsfile Corp. - December 16, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
Exposures COVID-19
Therma Bright Expands Manufacturing Capabilities To Meet New FDA EUA Guidance For AcuVid(TM)
Toronto, Ontario--(Newsfile Corp. - December 1, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Launches Benepod.com eCommerce Website
Toronto, Ontario--(Newsfile Corp. - November 24, 2021) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB Conditional Approval
Toronto, Ontario--(Newsfile Corp. - November 12, 2021) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Provides Update on FDA-EUA Application Process
Toronto, Ontario--(Newsfile Corp. - October 28, 2021) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Provides Update for its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario--(Newsfile Corp. - October 4, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical... 
Via Newsfile
Exposures COVID-19 Product Safety
Therma Bright Successfully Up-lists to the OTCQB Venture Market Under Symbol TBRIF
Toronto, Ontario--(Newsfile Corp. - September 14, 2021) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer... 
Via Newsfile
Exposures COVID-19 Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.